Company: HURA
Filing Date: 2025-11-03
Form Type: S-3
Source: 0001193125-25-262843
Chunk: 7

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-11-03
Form: S-3
Chunk 7
---
 the effects of the Kineta Merger on our business relationships, operating results and business generally; |

| • |     | expectations regarding the strategies, prospects, plans, expectations and objectives of our management for future 
 operations of our company following the closing of the Kineta Merger;                                             |

| • |     | unexpected costs, charges or expenses resulting from the Kineta Merger; |

| • |     | the cost, timing, scope and results of our clinical studies; |

| • |     | existing regulations and regulatory developments in the United States and other jurisdictions; |

| • |     | our ability to attract and retain key scientific, medical, commercial and management personnel; |

| • |     | our ability to obtain and maintain required regulatory approvals for our products; |

| • |     | our expectations regarding the use of our existing cash; |

| • |     | the therapeutic potential of IFx-Hu2.0,            
 IFx-Hu3.0, TBS-2025 and future product candidates; |

| • |     | the regulatory approval processes of the U.S. Food and Drug Administration and other comparable foreign                                                                                                                                                
 regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or 
 will be delayed in commercializing, such product candidates, and our ability to generate revenue will be materially impaired;                                                                                                                          |

| • |     | our ability to obtain or maintain patents or other appropriate protection for the intellectual property utilized 
 in our current and planned products; and                                                                         |

| • |     | our ability to develop and commercialize products without infringing the intellectual property rights of third 
 parties.                                                                                                       |

While we believe these expectations, assumptions, beliefs, estimates, projections, intentions, and strategies are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, most of which are difficult to predict and many of which are beyond our control. Actual results and timing of certain events may differ materially from those anticipated in these forward-looking statements as a 2

result of various factors. You should consider these factors carefully in evaluating forward-looking statements contained in this prospectus and the documents incorporated by reference into this
prospectus and are cautioned not to place undue reliance on such statements, which speak only as of the date of this prospectus. We undertake no obligation to update forward-looking statements, except as may